FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322755003> ?p ?o ?g. }

• W2322755003 abstract "Anticalins are high affinity scaffold proteins based on human lipocalins and represent a new class of biologics. Although lipocalins share limited sequence identity among each other they are all made up of a single conserved beta-barrel. The four loops protruding from the opening of the calyx contribute to the observed various binding functions of different lipocalins. The loop residues of human tear lipocalin were randomized to generate a combinatorial library and successive rounds of panning and screening were employed to generate an Anticalin with high affinity and specificity for VEGF-A, Angiocal. Angiocal was found to antagonize VEGF-A function by preventing its interaction with cognate membrane receptors. Following the initial characterization in cell-based and in vivo models as communicated previously (AACR 2008 #4077, AACR 2009 #2318) we sought to estimate the human pharmacokinetics of Angiocal by interspecies scaling. Therefore, PK profiles in mice, rats and cynomolgus monkeys were obtained and will be presented. Therapeutic antibodies such as bevacizumab are usually well tolerated while significant toxicities occur in a subset of patients, for example leading to an enhanced risk for thromboembolic events. It has been demonstrated that bevacizumab forms multimeric immune complexes in vivo which may be a cause for these effects. Furthermore, immune complex deposition in glomeruli of the kidney may cause glomerulosclerosis. With respect to thromboembolic complications of bevacizumab use, these were mirrored in human FcgammaIIa receptor transgenic mice where administration of complexes between heparin, Bevacizumab and heparin-binding isoforms of its VEGF-A target lead to platelet aggregation and thrombosis (Meyer, T. et al. J. Thromb. Haemost. 2009, 7: 171-181). Angiocal was tested in the same model and does not cause any of these adverse effects on platelets in vivo. GLP toxicology studies with Angiocal were performed in two relevant species to determine the NOAEL. In addition, we did not observe effects on inflammatory cytokines or complement factors in these studies while exaggerated pharmacodynamic effects consistent with potent VEGF neutralization were seen. Angiocal is currently undergoing phase Ib clinical testing in cancer patients to establish Anticalins as novel and safe class of therapeutic molecules. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3632. doi:10.1158/1538-7445.AM2011-3632" @default.
• W2322755003 created "2016-06-24" @default.
• W2322755003 creator A5019580546 @default.
• W2322755003 creator A5026963231 @default.
• W2322755003 creator A5027815157 @default.
• W2322755003 creator A5027975292 @default.
• W2322755003 creator A5028801597 @default.
• W2322755003 creator A5036908837 @default.
• W2322755003 creator A5051107256 @default.
• W2322755003 creator A5068499081 @default.
• W2322755003 creator A5087833147 @default.
• W2322755003 date "2011-04-15" @default.
• W2322755003 modified "2023-09-27" @default.
• W2322755003 title "Abstract 3632: Nonclinical pharmacokinetics and safety of Angiocal, the first VEGF-A-specific alternative scaffold protein entering clinical development for cancer" @default.
• W2322755003 doi "https://doi.org/10.1158/1538-7445.am2011-3632" @default.
• W2322755003 hasPublicationYear "2011" @default.
• W2322755003 type Work @default.
• W2322755003 sameAs 2322755003 @default.
• W2322755003 citedByCount "0" @default.
• W2322755003 crossrefType "proceedings-article" @default.
• W2322755003 hasAuthorship W2322755003A5019580546 @default.
• W2322755003 hasAuthorship W2322755003A5026963231 @default.
• W2322755003 hasAuthorship W2322755003A5027815157 @default.
• W2322755003 hasAuthorship W2322755003A5027975292 @default.
• W2322755003 hasAuthorship W2322755003A5028801597 @default.
• W2322755003 hasAuthorship W2322755003A5036908837 @default.
• W2322755003 hasAuthorship W2322755003A5051107256 @default.
• W2322755003 hasAuthorship W2322755003A5068499081 @default.
• W2322755003 hasAuthorship W2322755003A5087833147 @default.
• W2322755003 hasConcept C112705442 @default.
• W2322755003 hasConcept C121608353 @default.
• W2322755003 hasConcept C126322002 @default.
• W2322755003 hasConcept C150903083 @default.
• W2322755003 hasConcept C159654299 @default.
• W2322755003 hasConcept C20299238 @default.
• W2322755003 hasConcept C203014093 @default.
• W2322755003 hasConcept C207001950 @default.
• W2322755003 hasConcept C2776694085 @default.
• W2322755003 hasConcept C2777802072 @default.
• W2322755003 hasConcept C502942594 @default.
• W2322755003 hasConcept C71924100 @default.
• W2322755003 hasConcept C86803240 @default.
• W2322755003 hasConcept C98274493 @default.
• W2322755003 hasConceptScore W2322755003C112705442 @default.
• W2322755003 hasConceptScore W2322755003C121608353 @default.
• W2322755003 hasConceptScore W2322755003C126322002 @default.
• W2322755003 hasConceptScore W2322755003C150903083 @default.
• W2322755003 hasConceptScore W2322755003C159654299 @default.
• W2322755003 hasConceptScore W2322755003C20299238 @default.
• W2322755003 hasConceptScore W2322755003C203014093 @default.
• W2322755003 hasConceptScore W2322755003C207001950 @default.
• W2322755003 hasConceptScore W2322755003C2776694085 @default.
• W2322755003 hasConceptScore W2322755003C2777802072 @default.
• W2322755003 hasConceptScore W2322755003C502942594 @default.
• W2322755003 hasConceptScore W2322755003C71924100 @default.
• W2322755003 hasConceptScore W2322755003C86803240 @default.
• W2322755003 hasConceptScore W2322755003C98274493 @default.
• W2322755003 hasLocation W23227550031 @default.
• W2322755003 hasOpenAccess W2322755003 @default.
• W2322755003 hasPrimaryLocation W23227550031 @default.
• W2322755003 hasRelatedWork W1785345036 @default.
• W2322755003 hasRelatedWork W1848085765 @default.
• W2322755003 hasRelatedWork W2034390230 @default.
• W2322755003 hasRelatedWork W2042858467 @default.
• W2322755003 hasRelatedWork W2068562114 @default.
• W2322755003 hasRelatedWork W2069275094 @default.
• W2322755003 hasRelatedWork W2397244639 @default.
• W2322755003 hasRelatedWork W2443941107 @default.
• W2322755003 hasRelatedWork W2525938418 @default.
• W2322755003 hasRelatedWork W2570820825 @default.
• W2322755003 hasRelatedWork W2606499493 @default.
• W2322755003 hasRelatedWork W2914918388 @default.
• W2322755003 hasRelatedWork W2953854388 @default.
• W2322755003 hasRelatedWork W2966091297 @default.
• W2322755003 hasRelatedWork W3034712716 @default.
• W2322755003 hasRelatedWork W3039700461 @default.
• W2322755003 hasRelatedWork W3081927666 @default.
• W2322755003 hasRelatedWork W3083052481 @default.
• W2322755003 hasRelatedWork W3132908798 @default.
• W2322755003 hasRelatedWork W3137074556 @default.
• W2322755003 isParatext "false" @default.
• W2322755003 isRetracted "false" @default.
• W2322755003 magId "2322755003" @default.
• W2322755003 workType "article" @default.